Biotech company Invitae’s (NVTA) substantial revenue growth in its last reported quarter, and its progress in ushering personalized health monitoring into the mainstream, have impressed investors.

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company ...

* INVITAE CORP - WILL ACQUIRE ARCHERDX FOR UPFRONT CONSIDERATION CONSISTING OF 30 MILLION SHARES OF INVITAE COMMON STOCK AND $325 MILLION IN CASH * INVITAE CORP - OVERALL TRANSACTION VALUED AT ...

San Francisco-headquartered Invitae Corp NVTA defines itself as medical genetics company seeking to bring comprehensive genetic information into mainstream medicine, with the goal of improving ...

Between June 25 and October 30 the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 14 percentage points as investors worried over the possible ramifications of rising interest ...

In trading on Thursday, shares of Invitae Corp (Symbol: NVTA) crossed above their 200 day moving average of $20.28, changing hands as high as $23.39 per share. Invitae Corp shares are currently ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with ...

Invitae Corp. wants a piece of the prenatal screening pie, and the company just struck two deals to make that happen. Invitae Corp. wants to be a comprehensive provider of genetic information through ...

Labcorp beats Q2 profit and revenue estimates on demand for health tests Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic ...

Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s ...

Speaking on CNBC's "Closing Bell," Ark VInestment Management CEO Cathie Wood said Invitae Corp NVTA, in the molecular diagnostics space, is probably one of the most important companies in the genomic ...